DK3687567T3 - Anti-adrenomedullin (adm) bindemiddel til brug i behandling eller forebyggelse af sygdomssymptomer - Google Patents
Anti-adrenomedullin (adm) bindemiddel til brug i behandling eller forebyggelse af sygdomssymptomer Download PDFInfo
- Publication number
- DK3687567T3 DK3687567T3 DK18781997.4T DK18781997T DK3687567T3 DK 3687567 T3 DK3687567 T3 DK 3687567T3 DK 18781997 T DK18781997 T DK 18781997T DK 3687567 T3 DK3687567 T3 DK 3687567T3
- Authority
- DK
- Denmark
- Prior art keywords
- adrenomedullin
- adm
- binder
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17192999 | 2017-09-25 | ||
| EP17203370 | 2017-11-23 | ||
| PCT/EP2018/075987 WO2019057992A2 (en) | 2017-09-25 | 2018-09-25 | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3687567T3 true DK3687567T3 (da) | 2024-12-16 |
Family
ID=63722372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18781997.4T DK3687567T3 (da) | 2017-09-25 | 2018-09-25 | Anti-adrenomedullin (adm) bindemiddel til brug i behandling eller forebyggelse af sygdomssymptomer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220227854A1 (enExample) |
| EP (5) | EP3687567B1 (enExample) |
| JP (1) | JP7461875B2 (enExample) |
| KR (2) | KR20250004928A (enExample) |
| CN (2) | CN111511390B (enExample) |
| AU (3) | AU2018335438B2 (enExample) |
| BR (1) | BR112020005450A2 (enExample) |
| CA (1) | CA3076691A1 (enExample) |
| DK (1) | DK3687567T3 (enExample) |
| ES (1) | ES3001197T3 (enExample) |
| FI (1) | FI3687567T3 (enExample) |
| HR (1) | HRP20241795T1 (enExample) |
| HU (1) | HUE069945T2 (enExample) |
| IL (1) | IL273533A (enExample) |
| LT (1) | LT3687567T (enExample) |
| MX (1) | MX2020003538A (enExample) |
| MY (1) | MY204700A (enExample) |
| PL (1) | PL3687567T3 (enExample) |
| RS (1) | RS66415B1 (enExample) |
| SG (1) | SG11202002258WA (enExample) |
| SI (1) | SI3687567T1 (enExample) |
| WO (1) | WO2019057992A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021038078A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CA3168978A1 (en) * | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| US20210285949A1 (en) * | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| CN111893085A (zh) * | 2020-08-04 | 2020-11-06 | 北京臻溪谷医学研究中心（有限合伙） | 一种通过干细胞体外分化获得人工皮肤的方法及其应用 |
| KR20250040987A (ko) * | 2022-07-20 | 2025-03-25 | 상하이 제유 파마슈티칼 컴퍼니 리미티드 | 항-아드레노메둘린 비중화 항체, 이의 제조 방법 및 응용 |
| WO2025152915A1 (zh) * | 2024-01-16 | 2025-07-24 | 上海济煜医药科技有限公司 | 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CN1628126A (zh) | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| PT2298278E (pt) | 2002-06-07 | 2016-02-25 | Dyax Corp | Prevenção e redução da perda de sangue e resposta inflamatória |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| CN102711810B (zh) * | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| BR112012014417B1 (pt) | 2009-12-14 | 2021-11-09 | Scil Proteins Gmbh | Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| BR112014011670B1 (pt) * | 2011-11-16 | 2021-05-25 | Adrenomed Ag | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica |
| PL3553084T3 (pl) * | 2011-11-16 | 2023-04-17 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan |
| US9140696B2 (en) * | 2011-11-16 | 2015-09-22 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| ES2494190T3 (es) * | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| HRP20191771T1 (hr) | 2011-11-16 | 2019-12-27 | Adrenomed Ag | Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije |
| WO2014147153A1 (en) * | 2013-03-20 | 2014-09-25 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| KR20190120174A (ko) * | 2016-12-16 | 2019-10-23 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
-
2018
- 2018-09-25 US US16/650,474 patent/US20220227854A1/en active Pending
- 2018-09-25 PL PL18781997.4T patent/PL3687567T3/pl unknown
- 2018-09-25 LT LTEPPCT/EP2018/075987T patent/LT3687567T/lt unknown
- 2018-09-25 KR KR1020247040657A patent/KR20250004928A/ko active Pending
- 2018-09-25 AU AU2018335438A patent/AU2018335438B2/en active Active
- 2018-09-25 MX MX2020003538A patent/MX2020003538A/es unknown
- 2018-09-25 FI FIEP18781997.4T patent/FI3687567T3/fi active
- 2018-09-25 EP EP18781997.4A patent/EP3687567B1/en active Active
- 2018-09-25 RS RS20241461A patent/RS66415B1/sr unknown
- 2018-09-25 CA CA3076691A patent/CA3076691A1/en active Pending
- 2018-09-25 CN CN201880062062.1A patent/CN111511390B/zh active Active
- 2018-09-25 HR HRP20241795TT patent/HRP20241795T1/hr unknown
- 2018-09-25 ES ES18781997T patent/ES3001197T3/es active Active
- 2018-09-25 JP JP2020517143A patent/JP7461875B2/ja active Active
- 2018-09-25 EP EP24205659.6A patent/EP4488295A3/en active Pending
- 2018-09-25 SG SG11202002258WA patent/SG11202002258WA/en unknown
- 2018-09-25 EP EP21154857.3A patent/EP3854414A1/en not_active Withdrawn
- 2018-09-25 BR BR112020005450-0A patent/BR112020005450A2/pt unknown
- 2018-09-25 DK DK18781997.4T patent/DK3687567T3/da active
- 2018-09-25 EP EP22198106.1A patent/EP4159229A1/en active Pending
- 2018-09-25 CN CN202411206189.XA patent/CN119215164A/zh active Pending
- 2018-09-25 HU HUE18781997A patent/HUE069945T2/hu unknown
- 2018-09-25 SI SI201831189T patent/SI3687567T1/sl unknown
- 2018-09-25 MY MYPI2020001569A patent/MY204700A/en unknown
- 2018-09-25 EP EP22198142.6A patent/EP4159230A1/en active Pending
- 2018-09-25 WO PCT/EP2018/075987 patent/WO2019057992A2/en not_active Ceased
- 2018-09-25 KR KR1020207011620A patent/KR20200088302A/ko not_active Ceased
-
2020
- 2020-03-23 IL IL273533A patent/IL273533A/en unknown
-
2023
- 2023-03-09 AU AU2023201479A patent/AU2023201479A1/en not_active Abandoned
-
2026
- 2026-06-09 AU AU2026204409A patent/AU2026204409A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45192A (fr) | Traitement d'association | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3160476T3 (da) | Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner | |
| DK4374873T3 (da) | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande | |
| IL247111A0 (en) | Preventive or therapeutic agent for kidney disease | |
| SI3346995T1 (sl) | Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3261642T3 (da) | Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner | |
| IL240022A0 (en) | Titanium nitride hard mask and etch residue removal | |
| HUE060517T2 (hu) | Immunhiányos betegség kezelésére szolgáló eljárások | |
| IL273533A (en) | Antiadrenomedullin (ADM) binder for use in treating or preventing symptoms of disease | |
| DK3318251T3 (da) | Sammensætning til forebyggelse eller behandling af fedme eller lipidrelateret metabolisk sygdom | |
| DK3191103T3 (da) | Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner | |
| DK3630164T3 (da) | Dulaglutid til behandling af kronisk nyresygdom | |
| DK3297625T3 (da) | Forbindelse til profylakse eller behandling af diabetisk nefropati eller diabetisk nyresygdom | |
| CY2024037I2 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| ME02993B (me) | Laktoferin za upotrebu u dijagnozi ili prognozi alchajmerove bolesтi | |
| DK3270890T3 (da) | Cyclosporin-formuleringer til anvendelse ved forebyggelse eller behandling af kronisk afstødning af lungetransplantat | |
| DK3050574T3 (da) | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom | |
| FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
| DK3197556T3 (da) | Sammensætning til forebyggelse og/eller behandling af allergisymptomer | |
| DK3251675T3 (da) | Forebyggelse eller behandling af urinsyresygdom eller gigtsygdom | |
| SI3124048T1 (sl) | Sestavek za peroralno uporabo pri zdravljenju gastroezofagealne refluksne bolezni ali neugodja | |
| DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme |